CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
从抗 HER-2 到抗 HER-2 CAR-T 细胞：胃癌免疫治疗的演进策略
英文原题：From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.
查看英文原题
From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目前治疗手段未能改善胃癌（GC）患者生存。靶向人表皮生长因子受体2（HER2）是治疗晚期HER2阳性胃癌的可行策略。抗体药物偶联物、小分子酪氨酸激酶抑制剂（TKI）和双特异性抗体等新型药物形式正在出现，有望克服HER2靶向药物及单克隆抗体耐药。靶向HER2的嵌合抗原受体修饰T细胞（CAR-T）在胃癌和其他实体瘤中显示相当治疗潜力。然而，胃癌异质性高、肿瘤微环境（TME）复杂，常导致免疫逃逸，因此胃癌免疫治疗仍面临诸多挑战。本文回顾并讨论抗HER2 CAR-T 免疫治疗胃癌的研究进展。
展开英文摘要原文
Current Therapeutic modalities provide no survival advantage to gastric cancer (GC) patients. Targeting the human epidermal growth factor receptor-2 (HER-2) is a viable therapeutic strategy against advanced HER-2 positive GC.
Antibody-drug conjugates, small-molecule tyrosine kinase inhibitors (TKIs), and bispecific antibodies are emerging as novel drug forms that may abrogate the resistance to HER-2-specific drugs and monoclonal antibodies. Chimeric antigen receptor-modified T cells (CAR-T) targeting HER-2 have shown considerable therapeutic potential in GC and other solid tumors.
However, due to the high heterogeneity along with the complex tumor microenvironment (TME) of GC that often leads to immune escape, the immunological treatment of GC still faces many challenges.
Here, we reviewed and discussed the current progress in the research of anti-HER-2-CAR-T cell immunotherapy against GC.
论文信息
- 作者
- Sun J、Li X、Chen P、Gao Y
- 单位
- Department of Gastrointestinal Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People's Republic of China.China
- 文献类型
- 综述
- 期刊
- Journal of inflammation research2022
- 原文标识
- PubMed 35873388 · DOI 10.2147/JIR.S368138
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →